AMSTERDAM, November 9, 2015 /PRNewswire/ --
myTomorrows (Amsterdam, the
Netherlands) announced today that it has recently signed a
contract to collaborate with Hemispherx Biopharma, Inc.
(Philadelphia, USA; NYSE MKT: HEB) to provide access to its
natural alpha interferon for patients that have become intolerant
to treatment with recombinant interferon or where such treatment
fails.
Through myTomorrows' Internet-based platform, the product is now
made available to patients and doctors in Brazil, Columbia and Chile, through an Early Access Program.
In January 2012, ANMAT (the agency
responsible for the national regulation of drugs, foods and medical
technology in Argentina) approved
the product for treatment of hepatitis C, multiple sclerosis and
cancers in patients whose treatment with recombinant alpha
interferon fails or who become intolerant to treatment with
recombinant alpha interferon as a result of the appearance of
neutralizing antibodies. The US FDA and ANMAT also approved the
product for the treatment of refractory and recurring external
condylomata acuminate.
"We are pleased to include natural alpha interferon on our
platform and make the product available to physicians and patients
in three Latin-American countries" said Dr. Ronald Brus MD, founder and CEO of myTomorrows.
"Once the physician and patient have jointly decided to request
early access, we manage the complex and often time-consuming
process of receiving approval from regulatory authorities and
healthcare insurers and provide the product as quickly as
possible."
Dr. William Carter, Chairman and
CEO of Hemispherx said, "We are very happy to be able to provide a
treatment option for patients who have become intolerant to
recombinant interferon or for whom such treatment fails. It's great
that physicians and patients in Brazil, Columbia and Chile now have the opportunity to access our
product under the compassionate use regulations through the
internet-based platform of myTomorrows."
myTomorrows was founded by physicians and experts from the
pharmaceutical and technology industry to provide access to drugs
in development and diagnostic tests. By providing uniform public
information about early access programs, clinical trials and
diagnostic tests myTomorrows aims to enhance data-driven
decision-making and enable rational pharmacotherapy.
About myTomorrows
myTomorrows provides services to patients and physicians in need
of drugs in development and diagnostic tests. Through its
Internet-based platform, myTomorrows provides uniform public
information about early access programs, clinical trials and
diagnostic tests to enhance data-driven decision-making and enable
rational pharmacotherapy. myTomorrows also facilitates requests for
diagnostic tests and drugs in development. For more information
about myTomorrows, please visit the website
http://www.mytomorrows.com
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty
pharmaceutical company engaged in the manufacture and clinical
development of new drug entities for treatment of seriously
debilitating disorders especially life-threatening viruses.
Hemispherx's flagship products include Alferon N Injection® and the
experimental therapeutics rintatolimod and alpha interferon LDO.
Rintatolimod is an experimental RNA nucleic acid being developed
for globally important debilitating diseases and disorders of the
immune system, including Chronic Fatigue Syndrome. Hemispherx's
platform technology includes components for potential treatment of
various severely debilitating and life threatening diseases
including cancers.
Note for editors:
Please contact sir Erdem Yavuz
from myTomorrows for more information.
Phone: +31-88-525-38-88
E-mail: erdem.yavuz@mytomorrows.com
SOURCE myTomorrows